Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IDERA PHARMACEUTICALS, INC.

(IDRA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IDERA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

08/09/2021 | 04:10pm EDT

Item 2.02. Results of Operations and Financial Condition.

On August 9, 2021, Idera Pharmaceuticals, Inc. (the "Company") issued a press release announcing the Company's financial results for the first quarter ended June 30, 2021. As set forth below, the Company is furnishing the press release as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.


  Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



See the Exhibit Index below, which is incorporated by reference herein.



Exhibit No.                      Financial Statements and Exhibits.
  99.1          Press Release by the Company, dated August 9, 2021, furnished in
              accordance with Item 2.02 of this Current Report on Form 8-K.

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses

All news about IDERA PHARMACEUTICALS, INC.
08/09IDERA : Q2 Earnings Snapshot
AQ
08/09IDERA PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Provides Corpora..
AQ
08/09IDERA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/09IDERA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
08/09Idera Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June ..
CI
06/25IDERA PHARMACEUTICALS, INC.(NASDAQCM : IDRA) added to Russell 3000E Value Index
CI
06/25IDERA PHARMACEUTICALS, INC.(NASDAQCM : IDRA) dropped from Russell Microcap Growth Index
CI
06/25IDERA PHARMACEUTICALS, INC.(NASDAQCM : IDRA) added to Russell Microcap Value Index
CI
06/25IDERA PHARMACEUTICALS, INC.(NASDAQCM : IDRA) dropped from Russell 3000E Growth Index
CI
06/22IDERA PHARMACEUTICALS : Thinking about buying stock in Biocept, Histogen, Idera Pharmaceut..
PR
More news
Analyst Recommendations on IDERA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 89,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 0,50x
Yield 2021 -
Capitalization 49,6 M 49,6 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 32
Free-Float 78,3%
Chart IDERA PHARMACEUTICALS, INC.
Duration : Period :
Idera Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IDERA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,94 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Vincent J. Milano President, Chief Executive Officer & Director
John J. Kirby Chief Financial Officer & Senior Vice President
James Arthur Geraghty Chairman
Daniel B. Soland Chief Operating Officer & Senior Vice President
Mark Alan Goldberg Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IDERA PHARMACEUTICALS, INC.-74.39%50
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414